<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00352885</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00024759</org_study_id>
    <secondary_id>R01MH071580</secondary_id>
    <secondary_id>DATR A3-NSS</secondary_id>
    <nct_id>NCT00352885</nct_id>
  </id_info>
  <brief_title>Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment</brief_title>
  <official_title>IL-2 Neuropsychiatric Symptoms: Mechanism and Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the effectiveness of an antidepressant in preventing or reducing
      depressive symptoms in people with melanoma who are receiving Interleukin-2 (IL-2) treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melanoma is the most serious type of skin cancer, affecting nearly 54,000 people in the
      United States each year. Melanomas often develop in pre-existing moles or as new moles on the
      body. If left untreated, the cancerous cells can spread throughout the body. Fortunately,
      melanoma can be cured if a person is diagnosed and treated early. Typical treatments include
      surgery, amputation, chemotherapy, and immunotherapy. Interleukin-2 (IL-2) treatment, a type
      of immunotherapy, uses the body's immune system to slow or stop the spread of cancer cells to
      other parts of the body. However, IL-2 treatment is typically associated with severe side
      effects, including depression, fatigue, and difficulty thinking. This study will evaluate
      whether escitalopram, an antidepressant, can help improve treatment-related depressive
      symptoms, reduce stress hormone levels, and increase the number of treatment cycles among
      people with metastatic melanoma who are receiving IL-2 treatment.

      Participation in this double-blind study will last up to 18 weeks and will include 5 to 14
      study visits. Participants will complete four 1-week cycles of IL-2 treatment over a 12-week
      period. Two weeks prior to starting IL-2 treatment, participants will undergo a psychiatric
      interview; a computerized thinking test; questionnaires; and blood, urine, and saliva
      collection. Participants will also be randomly assigned to start receiving either
      escitalopram or placebo for the entire duration of the study. The dosage of escitalopram or
      placebo will vary depending on the symptom severity of each participant. Immediately prior to
      IL-2 treatment, participants will undergo preliminary IL-2 procedures, which will include a
      medical history review, physical exam, and blood collection. These same procedures will occur
      every day that the participant is in the hospital for IL-2 treatment. Participants will stay
      in the hospital when receiving all four IL-2 treatment cycles. During these hospital stays,
      participants will complete repeat questionnaires and computerized tasks. Blood collection
      will occur at selected times as well. A follow-up visit will occur 4 weeks after the final
      treatment dose of IL-2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of IL-2 Treatments Tolerated</measure>
    <time_frame>Measured over 5 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuroendocrine System Functioning and Stress Hormone Levels</measure>
    <time_frame>Measured over 5 months of IL-2 treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune System Functioning</measure>
    <time_frame>Measured over 5 months of IL-2 treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serotonin Metabolism</measure>
    <time_frame>Measured over 5 months of IL-2 treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Functioning, as Assessed by Computerized Neuropsychological Testing</measure>
    <time_frame>Measured on Day 2 of each IL-2 cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic Polymorphisms</measure>
    <time_frame>Measured before and after IL-2 treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive escitalopram and IL-2 treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo and IL-2 treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>Participants will begin medication approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 10 mg per day. If 10 mg is well tolerated by the participant, the dosage will be increased to 20 mg per day. The dosage for the remainder of the study will be 20 mg per day.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will begin the placebo approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 1 pill per day, if 1 pill is well tolerated by the participant the dosage will be increased to 2 pills per day. Two pills per day will be the dosage for the reminder of the study.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL-2</intervention_name>
    <description>IL-2 is a 12-week treatment regimen with intravenous (IV) IL-2. There will be one cycle every 3 weeks for a total of four cycles. One cycle is 720,000 units/kg every 8 hours for 5 days.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with cancer and beginning Interleukin (IL)-2 treatment

          -  Willing to use an effective form of birth control throughout the study if sexually
             active

        Exclusion Criteria:

          -  Diagnosed with major depression or experiencing significant depressive symptoms or a
             Hamilton Rating Scale-Depression score of 18 or higher

          -  Brain metastases, history of a brain injury, or seizure disorders

          -  Meets Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria for
             substance abuse or dependence within 3 months of study entry

          -  Suicidal, psychotic, or received psychiatric hospitalization within 12 months of study
             entry

          -  Past or current history of schizophrenia or bipolar disorder

          -  Pregnant or planning on becoming pregnant within 1 to 2 years

          -  Evidence of untreated or poorly controlled infectious, hormone, heart, blood, kidney,
             liver, or neurological disease

          -  Use of antidepressants, glucocorticoids, guanethidine, centrally acting
             alpha-antagonists, beta-blockers, or anticonvulsants

          -  Clinically significant eye abnormalities

          -  A score lower than 28 on the Mini Mental Status Exam (MMSE)

          -  Prior history of severe adverse events associated with escitalopram or other selective
             serotonin reuptake inhibitor (SSRI) antidepressants

          -  Diagnosed with type 1 or type 2 diabetes

          -  Any condition that might make the participant unsuitable for enrollment or that could
             interfere with study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique L. Musselman, MD,MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Lawson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Miller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2006</study_first_submitted>
  <study_first_submitted_qc>July 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2006</study_first_posted>
  <results_first_submitted>March 8, 2014</results_first_submitted>
  <results_first_submitted_qc>May 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2014</results_first_posted>
  <last_update_submitted>October 2, 2014</last_update_submitted>
  <last_update_submitted_qc>October 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Andrew H Miller</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>IL-2 therapy</keyword>
  <keyword>Antidepressant</keyword>
  <keyword>Immune system</keyword>
  <keyword>Neuroendocrine response</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Escitalopram</title>
          <description>Participants will receive escitalopram 10-20 mg/day 2 weeks before and during IL-2 treatment</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants will receive placebo 2 weeks before and during IL-2 treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Escitalopram</title>
          <description>Participants will receive escitalopram and IL-2 treatment</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants will receive placebo and IL-2 treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.8" spread="8.4"/>
                    <measurement group_id="B2" value="44.6" spread="16.1"/>
                    <measurement group_id="B3" value="47.4" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of IL-2 Treatments Tolerated</title>
        <time_frame>Measured over 5 months of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram</title>
            <description>Participants will receive escitalopram and IL-2 treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo and IL-2 treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of IL-2 Treatments Tolerated</title>
          <units>one IL-2 injection of 720,000 units/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="8.22"/>
                    <measurement group_id="O2" value="19.8" spread="8.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuroendocrine System Functioning and Stress Hormone Levels</title>
        <time_frame>Measured over 5 months of IL-2 treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune System Functioning</title>
        <time_frame>Measured over 5 months of IL-2 treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serotonin Metabolism</title>
        <time_frame>Measured over 5 months of IL-2 treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serotonin Metabolism</title>
        <time_frame>Measured over 5 months of IL-2 treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Functioning, as Assessed by Computerized Neuropsychological Testing</title>
        <time_frame>Measured on Day 2 of each IL-2 cycle</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genetic Polymorphisms</title>
        <time_frame>Measured before and after IL-2 treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Escitalopram</title>
          <description>Participants will receive escitalopram and IL-2 treatment</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants will receive placebo and IL-2 treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Progression of melanoma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac effect</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bobbi Woolwine</name_or_title>
      <organization>Emory University</organization>
      <phone>404-712-9620</phone>
      <email>bwoolwi@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

